Safety and immune response of COVID-19 vaccination in patients with chronic hepatitis B virus infection

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100047936

Enrollment

Unknown

Registered

2021-06-28

Start date

2021-07-01

Completion date

Unknown

Last updated

2022-03-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic hepatitis B virus (HBV) infection

Interventions

Chronic HBV infection group:COVID-19 vaccine

Healthy control group:COVID-19 vaccine

Eligibility

Sex/Gender

All

Age

18 Years to 59 Years

Inclusion criteria

Inclusion criteria: 1. Chronic HBV infection group: (1) Chronic HBV infection; (2) Aged 18-59 years; (3) Voluntarily participate in the project. 2. Healthy control group: (1) No HBV infection; (2) Aged 18-59 years; (3) Voluntarily participate in the project.

Exclusion criteria

Exclusion criteria: 1. Past history of new coronary pneumonia/suspected case/close contact history of new coronary patients; 2. The use of hormones, cyclosporine, immunoglobulin and other drugs that affect immunity in the past two months; 3. Contraindications to the new crown vaccination.

Design outcomes

Primary

Measure	Time frame
Anti-SARS-CoV-2 antibody;SARS-CoV-2-specific memory B cell;	—

Secondary

Measure	Time frame
Liver function;HBV DNA;HBV serologic markers;	—

Countries

China

Contacts

Public ContactRen Hong

Institute for Viral Hepatitis, Chongqing Medical University

renhong0531@cqmu.edu.cn+86 23 63693029

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026